Skip to content
Disclosery

MWG Management Ltd.

Follow

13F filer, CIK 1845151, Washington, DC

MWG Management Ltd. reported $81,319,135 across 3 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-12.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-25-277944

Period
2025-09-30
Reported value
$81.3M
Holdings
3
Top 10 weight
100%
New
1
Sold out
1

Largest buys vs the previous quarter

SecurityShares changeApprox. value
LYELnew+1,008,116$16.4M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
LYELL IMMUNOPHARMA INCexited-1,008,116-$8.91M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0001193125-25-277944, largest first. % of portfolio is the value over $81,319,135, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
BEAMBEAM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: 2,346,934 shares; 2024Q1: 2,346,934 shares; 2024Q2: 2,266,934 shares; 2024Q3: 2,266,934 shares; 2024Q4: 2,266,934 shares; 2025Q1: 2,266,934 shares; 2025Q2: 2,266,934 shares; 2025Q3: 2,266,934 shares 2,266,934$55M67.66%0Timeline
LYELLYELL IMMUNOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: not reported; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,008,116 shares 1,008,116$16.4M20.13%newTimeline
PRMEPRIME MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: 1,792,210 shares; 2024Q1: 1,792,210 shares; 2024Q2: 1,792,210 shares; 2024Q3: 1,792,210 shares; 2024Q4: 1,792,210 shares; 2025Q1: 1,792,210 shares; 2025Q2: 1,792,210 shares; 2025Q3: 1,792,210 shares 1,792,210$9.93M12.21%0Timeline

Sold out in Q3 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
LYELL IMMUNOPHARMA INCLYELL IMMUNOPHARMA INC1,008,116$8.91Mshares

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-25-277944 base2025-11-12acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001193125-25-277944 Quarter ended 2025-09-302025-11-12acceptance time not in the bulk data set
13F-HR 0000950123-25-008264 Quarter ended 2025-06-302025-08-14acceptance time not in the bulk data set
13F-HR 0000950123-25-004952 Quarter ended 2025-03-312025-05-13acceptance time not in the bulk data set
13F-HR 0000950123-25-002628 Quarter ended 2024-12-312025-02-14acceptance time not in the bulk data set
13F-HR 0000950123-24-010641 Quarter ended 2024-09-302024-11-08acceptance time not in the bulk data set
13F-HR 0000950123-24-008094 Quarter ended 2024-06-302024-08-13acceptance time not in the bulk data set
13F-HR 0000950123-24-005128 Quarter ended 2024-03-312024-05-14acceptance time not in the bulk data set
13F-HR 0000950123-24-002084 Quarter ended 2023-12-312024-02-14acceptance time not in the bulk data set
13F-HR 0000950123-23-010382 Quarter ended 2023-09-302023-11-14acceptance time not in the bulk data set
13F-HR 0000950123-23-007815 Quarter ended 2023-06-302023-08-14acceptance time not in the bulk data set
13F-HR 0000950123-23-005049 Quarter ended 2023-03-312023-05-15acceptance time not in the bulk data set
13F-HR 0000950123-23-002243 Quarter ended 2022-12-312023-02-14acceptance time not in the bulk data set
13F-HR 0000950123-22-011914 Quarter ended 2022-09-302022-11-14acceptance time not in the bulk data set
13F-HR 0000950123-22-008905 Quarter ended 2022-06-302022-08-15acceptance time not in the bulk data set
13F-HR 0000950123-22-006032 Quarter ended 2022-03-312022-05-16acceptance time not in the bulk data set
13F-HR 0000950123-22-002933 Quarter ended 2021-12-312022-02-14acceptance time not in the bulk data set
13F-HR 0000950123-21-015317 Quarter ended 2021-09-302021-11-15acceptance time not in the bulk data set
13F-HR 0000950123-21-011383 Quarter ended 2021-06-302021-08-16acceptance time not in the bulk data set
13F-HR 0000950123-21-006871 Quarter ended 2021-03-312021-05-17acceptance time not in the bulk data set
13F-HR 0000950123-21-002962 Quarter ended 2020-12-312021-02-17acceptance time not in the bulk data set